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his colleagues argue in the ﬁ nal report of The Lancet–
University of Oslo Commission on Global Governance 
for Health.2 They are about power. They are about elites. 
And they are about a rigid consensus among these 
powerful elites that prevents most attempts to question 
the norms on which political decisions are made. Yet 
elites are only as powerful as the systems that support 
the status quo. And global systems, such as those in 
trade, investment, or security, should (but do not 
always) have mechanisms for civil society participation 
and links with international norms that already exist to 
protect health.
The Commission addresses seven political domains 
that shape health and contribute to inequity within 
populations: ﬁ nance, intellectual property, trade and 
investment treaties, food, corporate activity, migration, 
and armed conﬂ ict. It examines the obstacles to eﬀ ective 
global governance for health. And ﬁ nally, it proposes 
mechanisms to improve the accountability of all those 
who inﬂ uence health through these diﬀ erent sectors. 
Proposals that could better articulate a way in which 
civil society engages in global policy, together with ideas 
for how international institutions could be mandated to 
produce health equity impact assessments, are worthy 
of consideration and debate. 
The Commission includes contributors from 
13 countries, including India, Brazil, Thailand, Tanzania, 
Ghana, Namibia, South Africa, and the occupied 
Palestinian territory. They have provided an opportunity 
to pause and reﬂ ect on a problem of emerging and 
serious importance. The era after the Millennium 
Development Goals is one that will be substantially 
more complex than today. The link between poverty 
and sustainability is not simple. Exclusive anti-poverty 
measures will not solve some of the biggest health 
threats people face. Solutions will require speciﬁ c input 
from diﬀ erent regions, countries, and individuals—
and a more critical understanding than has hitherto 
been displayed by policy makers of the determinants 
of human survival and wellbeing. Success will demand 
courage and ﬂ exibility to challenge the consensus that 
so inhibits the changes needed to bring about greater 
equity. This Commission can, we hope, be a contribution 
to this need for greater critical understanding and 
challenge.
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Intraoperative radiotherapy was developed to opti-
mise local outcomes of radiotherapy because it 
oﬀ ers excellent delineation of the tumour bed under 
visual control, very good dose homogeneity, and 
spares normal tissue.1 The technique was applied to 
many tumour sites with controversial results,2 and 
initial reports by French3 and US4 teams showed that 
intraoperative radiotherapy for breast cancer led to 
increased rates of local recurrence compared with 
whole-breast irradiation of 50 Gy given in daily fractions 
over 5 weeks plus an external boost of 10–16 Gy to the 
tumour bed, which oﬀ ers excellent local tumour control, 
with local recurrence of about 6% after 10-year median 
follow-up.5,6 Despite increased risk of local recurrence, 
intraoperative radiotherapy remains an attractive 
option for some patients because it removes the need 
to attend a radiotherapy centre for 25–33 fractions for 
whole-breast irradiation.
In The Lancet, Jayant Vaidya and colleagues7 present 
results of the TARGIT-A trial, while in The Lancet 
Oncology, Umberto Veronesi and colleagues8 present 
results of the ELIOT trial. Each trial compared a 
diﬀ erent type of intraoperative radiotherapy with 
external whole-breast irradiation. Both groups of 
authors should be commended for their work in this 
very challenging area.
The TARGIT-A ﬁ ndings add to the ﬁ rst report.9 This 
non-inferiority study compared one intraoperative 
Intraoperative radiotherapy for breast cancer
Published Online
November 11, 2013
http://dx.doi.org/10.1016/
S0140-6736(13)62304-1
See Articles page 603
See Online/Articles
Lancet Oncol 2013; published 
online November 11.
http://dx.doi.org/10.1016/
S1470-2045(13)70497-2
Copyright © Azria and Lemanski. 
Open Access article distributed 
under the terms of CC BY
Comment
www.thelancet.com   Vol 383   February 15, 2014 579
dose of 20 Gy using a spherical applicator (point source 
of 50 kV energy x-rays) with whole-breast irradiation 
using tangential ﬁ elds without node irradiation. The 
predeﬁ ned non-inferiority margin was an absolute 
diﬀ erence of 2·5% in local recurrence in the conserved 
breast between groups. Initially, intraoperative radio-
therapy was delivered concurrently with lumpectomy 
(prepathology stratum, n=2298), but some centres 
delivered intraoperative radio therapy as a second 
procedure after deﬁ nitive tu mour pathology reports, 
to improve selection of patients and allow enrolment 
of patients after lump ectomy (postpathology 
stratum, n=1153). Overall, the 5-year risks for local 
recurrence in the conserved breast for intraoperative 
radiotherapy versus whole-breast irradiation were 
3·3% (95% CI 2·1–5·1) versus 1·3% (0·7–2·5; p=0·042). 
These results are acceptable in terms of the threshold 
of the predeﬁ ned non-inferiority margin. In the 
prepathology stratum, local recurrence was 2·1% 
(95% CI 1·1–4·2) with intraoperative radiotherapy and 
1·1% (0·5–2·5) with whole-breast irradiation (p=0·31). 
This particularly important ﬁ nding conﬁ rms the need 
for concomitant delivery of intraoperative radiotherapy 
and lumpectomy.
By contrast, ELIOT8 did not allow a postpathology 
procedure. The authors randomised 1305 patients 
after quadrantectomy to receive either whole-breast 
irradiation (50 Gy in 25 fractions followed by a boost 
of 10 Gy in ﬁ ve fractions using an external electron 
beam without node irradiation) or intraoperative 
radiotherapy with electrons (21 Gy in one fraction to 
the tumour bed using electrons of 6–9 MeV, prescribed 
to the 90% isodose). Local recurrence of less than 7·5% 
in the intraoperative radiotherapy group was deemed 
to show equivalent eﬃ  cacy compared with whole-
breast irradiation; the primary outcome was occurrence 
of ipsilateral breast tumour recurrence (IBTR). After 
median follow-up of 5·8 years, the 5-year event rate 
for IBTR was 4·4% (95% CI 2·7–6·1) with intraoperative 
radiotherapy and 0·4% (0·0–1·0) with whole-breast 
irradiation. Thus, the rate of local recurrence with 
intraoperative radiotherapy was within the prespeciﬁ ed 
equivalence margin, but was signiﬁ cantly worse than 
that for whole-breast irradiation. Perhaps the most 
important information gained from these results 
regards the site of IBTR: the authors distinguished 
true local relapses from new ipsilateral breast tumours 
outside the index quadrant. Occurrence of true local 
relapses (p=0·0003), local relapses outside the index 
quadrant (p=0·0001), and axillary or regional lymph 
node metastases (p=0·03) were signiﬁ cantly increased 
with intraoperative radiotherapy.
Of 35 local recurrences in the intraoperative radio-
therapy group of ELIOT, 14 (40%) occurred outside the 
index quadrant and 21 (60%) were true local recur-
rences. In the prepathology stratum of the TARGIT-A 
trial, the crude number of local recurrences was ten 
of 2234 patients. However, when examining tumour 
charac teristics in TARGIT-A versus ELIOT, 12% versus 
14% were 2 cm or bigger, 17% versus 26% were node 
positive, and 15% versus 20% were grade 3, making 
comparisons diﬃ  cult. In a multivariable analysis of the 
ELIOT results,8 tumour size, the presence of four or more 
positive nodes, a poorly diﬀ erentiated tumour, and 
triple-negative subtype were associated with increased 
likelihood of IBRT. These data are in accordance with 
the patient selection criteria in our phase 2 trial.10 The 
American Society for Radiation Oncology (ASTRO) 
task force recommendations11 also conﬁ rmed that the 
most relevant inclusion criteria for accelerated partial-
breast irradiation were: age 60 years or older, tumour 
size 2 cm or less, and invasive ductal carcinoma that 
is T1N0 and oestrogen-receptor positive. Selection 
of patients might aﬀ ect the ﬁ nal margin status.12 An 
absence of information about margins at the time 
of irradiation is a frequent criticism of intraoperative 
radiotherapy and, unfortunately, these margins were 
not described in either study.
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The main diﬃ  culty encountered in comparing the 
ELIOT and TARGIT-A results is the diﬀ erence between 
both conventional whole-breast irradiation groups. In 
ELIOT, whole-breast irradiation included a systematic 
10 Gy electron boost, whereas no information was avail-
able from TARGIT-A concerning the number of patients 
who received a boost after whole-breast irradiation. In 
ELIOT, only four (0·6%) of 654 patients in the whole-
breast irradiation group had a local recurrence, which 
is excellent in comparison with the group given a 16 Gy 
boost in the EORTC boost trial5 (4·0% [95% CI 3·3–4·6] 
in T1 and 4·5% [3·9–5·2] in T2 tumours).
After intraoperative radiotherapy, discovery of deﬁ ni-
tive adverse histological features theoretically requires 
additional postoperative external irradiation. That 
was the case for 22% (219 of 1012) of patients in the 
prepathology stratum of TARGIT-A and for 5% (31 of 
647) of patients in ELIOT. Interpretation of the eﬀ ect of 
additional whole-breast irradiation is diﬃ  cult because 
the ELIOT protocol speciﬁ ed additional irradiation only 
for patients with four or more positive axillary nodes. 
Surprisingly, additional irradiation was only delivered 
to the aﬀ ected breast in both studies, whereas in 
clinical practice, the breast and supraclavicular and 
internal mammary chain nodes are normally irradiated. 
This decision might partly explain the poor eﬀ ect of 
additional irradiation on breast-cancer mortality in 
TARGIT-A (8% when intraoperative radiotherapy was 
followed by whole-breast irradiation vs 1·8% with 
intraoperative radiotherapy alone in low-risk patients). 
In September, 2013, Poortmans and colleagues13 pre-
sented results of EORTC trial 22922-10925, which 
investigated the contribution of radiotherapy to 
the internal mammary and medial supraclavicular 
lymph nodes (IM-MS) in terms of overall survival, 
disease-free survival, and metastasis-free survival. 
4004 patients were randomised to whole-breast and 
IM-MS radiotherapy or whole-breast radiotherapy 
alone. IM-MS radiotherapy improved outcomes at 
10 years: overall survival 82·3% versus 80·7% (HR 0·87), 
disease-free survival 72·1% versus 69·1% (HR 0·89), and 
metastasis-free survival 78% versus 75% (HR 0·86).13 The 
treatment eﬀ ect on overall survival was independent 
from the number of involved lymph nodes. 
Other notable points are that nearly 75% of patients 
received adjuvant hormone therapy alone in ELIOT 
(72% in TARGIT-A), which might be insuﬃ  cient since 
adjuvant chemotherapy is deemed necessary for 
many patients presenting with hormone-receptor 
positive tumours.14 Also, in ELIOT, the presence of 
more than 1% of immuno reactive cells was deﬁ ned 
as hormone-receptor positivity. Had a higher 
threshold been speciﬁ ed as in many other trials, a 
non-negligible number of patients would have been 
deﬁ ned as hormone-receptor nega tive and thus been 
given adjuvant chemotherapy, potentially leading to 
improved breast-cancer mortality. Importantly, the 
median follow-up durations of 2 years and 5 months 
for TARGIT-A and of 5·8 years for ELIOT are too short 
to draw deﬁ nitive conclusions about the risk of breast-
cancer death, particularly in patients selected outside 
the ASTRO recommendations.
One argument might be that in the low-risk popu-
lations included in ELIOT and TARGIT-A, adjuvant 
radiotherapy is unnecessary because no beneﬁ cial eﬀ ect 
on breast-cancer-related mortality has been shown.15 
However, we do not support omission of radiotherapy 
after lumpectomy in view of the increased rate of IBTR 
over time in the absence of radiotherapy, and the life 
expectancy of patients diagnosed after 65 years, who 
are likely to live long enough to experience recurrence 
and metastatic disease. Intraoperative radiotherapy has 
few side-eﬀ ects and thus might be an attractive option 
for some low-risk patients.
One way to improve the acceptability of external 
radiotherapy might be to reduce either the number 
of fractions or the irradiated volume, with or without 
shortening overall treatment time.16,17 Studies with at 
least 10 years of median follow-up16,17 have conﬁ rmed 
that hypofractionation in radiotherapy for breast cancer 
is safe and eﬀ ective. These approaches are increasingly 
being used in clinical practice, but only for patients 
who are not suitable for protracted radiotherapy or 
intraoperative radiotherapy. Indeed, it is most often 
proposed to patients aged between 55 and 65 years 
presenting with tumours of less than 2 cm and node 
negative disease. Hypofractionated radiotherapy is 
convenient for patients and has reduced waiting lists in 
many centres.18
The new data from TARGIT-A and ELIOT reinforce our 
conviction that intraoperative radiotherapy during breast-
conserving surgery is a reliable alternative to conventional 
postoperative fractionated irradiation, but only in a 
carefully selected population at low risk of local recurrence. 
Comment
www.thelancet.com   Vol 383   February 15, 2014 581
*David Azria, Claire Lemanski
Department of Radiation Oncology and INSERM U896, 
Institut du Cancer Montpellier, 34298 Montpellier, France 
david.azria@icm.unicancer.fr
We declare that we have no conﬂ icts of interest. 
1 Gunderson LL, Cohen AC, Dosoretz DD, et al. Residual, unresectable, or 
recurrent colorectal cancer: external beam irradiation and intraoperative 
electron beam boost +/- resection. Int J Radiat Oncol Biol Phys 1983; 
9: 1597–606.
2 Dubois JB, Bussieres E, Richaud P, et al. Intra-operative radiotherapy of 
rectal cancer: results of the French multi-institutional randomized study. 
Radiother Oncol 2011; 98: 298–303.
3 Dubois JB, Hay M, Gely S, et al. IORT in breast carcinomas. 
Front Radiat Ther Oncol 1997; 31: 131–37.
4 Merrick HW 3rd, Battle JA, Padgett BJ, et al. IORT for early breast cancer: 
a report on long-term results. Front Radiat Ther Oncol 1997; 31: 126–30.
5 Bartelink H, Horiot JC, Poortmans PM, et al. Recurrence rates after 
treatment of breast cancer with standard radiotherapy with or without 
additional radiation. N Engl J Med 2001; 345: 1378–87.
6 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Eﬀ ect of 
radiotherapy after breast-conserving surgery on 10-year recurrence and 
15-year breast cancer death: meta-analysis of individual patient data for 
10 801 women in 17 randomised trials. Lancet 2011; 378: 1707–16.
7 Vaidya JS, Wenz F, Bulsara M, et al, on behalf of the TARGIT trialists’ group. 
Risk-adapted targeted intraoperative radiotherapy versus whole-breast 
radiotherapy for breast-cancer: 5-year results for local control and overall 
survival from the TARGIT-A randomised trial. Lancet 2013; published online 
Nov 11. http://dx.doi.org/10.1016/S0140-6736(13)61950-9.
8 Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy 
versus external radiotherapy for early breast cancer (ELIOT): a randomised 
controlled equivalence trial. Lancet Oncol 2013; published online Nov 11. 
http://dx.doi.org/10.1016/S1040-2045(13)70497-2.
The goal of treatment of arteriovenous malformations 
is to eliminate risk of intracerebral haemorrhage 
and to preserve functional status. After diagnosis 
of an unruptured or asymptomatic arteriovenous 
malformation, the patient can be conservatively 
monitored with the understanding that future 
haemorrhage or seizure might occur. Alternatively, 
treatment can be oﬀ ered such that long-term 
beneﬁ ts of cure are weighed against the risks of that 
intervention. Microsurgery, endovascular embolisation, 
and radiosurgery are three major forms of intervention 
for arteriovenous malformations, and they have been 
used successfully as individual interventions and in 
combinations. Irrespective of the technique chosen, the 
ultimate goal is complete obliteration of the origin of the 
arteriovenous malformation (nidus obliteration), because 
subtotal treatment does not confer protection against 
future haemorrhage and can worsen disease history.
For unruptured arteriovenous malformations, existing 
guidelines for treatment, long-term natural history, and 
outcomes of haemorrhage are controversial. A study1 
of patients harbouring arteriovenous malformations 
without evidence of previous haemorrhage suggested 
that there was no diﬀ erence in outcome between 
treated and untreated patients at the end of the third 
year of follow-up. This ﬁ nding shows the need for 
further clariﬁ cation of the natural history of the disorder 
and optimum management strategies for unruptured 
arteriovenous malformations.
In this issue of The Lancet, Jay Mohr and colleagues2 
present a prospective, multicentre, randomised trial 
comparing the eﬃ  cacy of medical management plus 
interventional therapy (which included microsurgery, 
embolisation, or radiosurgery, or combinations of 
these techniques) versus medical management alone 
(the ARUBA trial). The form of interventional therapy 
was determined by the treating physicians in the trial. 
The primary endpoint of the study was time until 
death or stroke, and the secondary endpoint was death 
or disability at 5 years. Enrolment was halted after 
33 months, when data for 223 patients were available, 
because of apparently better outcomes of patients 
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